Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)


Epic Research & Diagnostics




Coronary Artery Disease
Cardiovascular Diseases

Study type


Funder types




Details and patient eligibility


The objective of this study is to explore the relationship between the ClearView scan results and a variety of cardiovascular risk indicators such as the Coronary Calcium Score, Framingham Risk Factors, Reynolds Risk Score, and biomarkers of inflammation. The ClearView device is a bio-electrographic tool that may assist medical professionals in rapid assessment of the systemic origin of the patient's presenting symptom(s). The ClearView is a potentially valuable resource that may benefit a physician's office by offering expedited differentiation capabilities. The subsequent results have the potential to include more data that would allow rapid patient diagnosis, triage, and treatment; optimized precious resource expenditure (nursing, physician, etc.); lower costs to facility, patient and insurance company; and decreased office wait time.


60 estimated patients




18 to 85 years old


No Healthy Volunteers

Inclusion criteria

  • Sex: Male or Female
  • Age range: 18 to 85
  • Patients who are recommended for and who have had a cardiac CT study that produces a Coronary Calcium Score within 30 days prior to the ClearView Scan or plan to have the CT within 14 days after the ClearView Scan.
  • Patients who have had a blood test resulting in hs-CRP, fasting lipid panel and MPO results within 6 months prior to the ClearView Scan or plan to have the tests done within 14 days after the ClearView Scan.
  • The patient or legal representative is able to understand and provide signed consent for the procedure.

Exclusion criteria

  • Patients with pacemakers or another implanted electrical device, such as an automatic internal cardiac defibrillator.

    • Patients connected to an electrical device that cannot be removed or temporarily powered off (i.e. monitor) during subject testing with the ClearView Device
    • Vulnerable populations
    • Patients actively being treated for cancer or with a previous diagnosis of cancer that required chemotherapy, radiation therapy or hormonal therapy.
    • Patients missing all or any part of a fingertip (excluding fingernail).
    • Patients with involuntary hand tremors /shaking of the hands that may prevent clear imaging.

Trial design

60 participants in 1 patient group

Cardiac Risk
Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems